Imtesty,

I haven't seen anything published or presented that more directly explores BET inhibitors and insulin resistance/sensitivity other than the Australian pre-diabetes study that you cited (patients treated for 30 days) and the effects on plasma glucose after the 6 month SUSTAIN/ASSURE studies. It could be direct effects on key glucose metabolism or insulin signaling genes. Or it could be indirect effects via decreased inflammation, changes in HDL particle number, size,  composition (ie lipidome), or other yet to be discovered or disclosed pathway that is responsible for the glucose metabolism effects of apabetalone. Also, glucose homeostasis is influenced by many tissues (liver, muscle, fat, brain, pancreas, etc) so determining what tissue(s) are responding to apabetalone to elicit glucose/insulin sensitivity changes would be important. Also, for Alzheimers, it's not clear if it is the modulation of apoAI/HDL, inflammation, insulin sensitivity, or another pathway that is responsible for the potential protection against Alzheimers.

Just my opinion,

BearDownAZ